trending Market Intelligence /marketintelligence/en/news-insights/trending/v-1BCtOKcG-gsAt8LWMA0Q2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Helix BioPharma, ProMab to collaborate on cell-based therapies

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Helix BioPharma, ProMab to collaborate on cell-based therapies

Helix Biopharma Corp. will collaborate with ProMab Biotechnologies Inc. to develop cell-based therapies.

Under a nonbinding letter of intent, the companies will complete a due diligence and establish a collaboration to develop chimeric antigen receptor T cell therapy for hematological malignancies and solid tumors.